National AIDS Treatment Advocacy Project Hydroxyurea with ddI or ddI/d4T: a novel approach to HIV therapy
ثبت نشده
چکیده
Results from several hydroxyurea (ddI+hydroxyurea) studies were reported at Vancouver (July `96) and ICAAC (September, `96). Our Vancouver and ICAAC Conference daily highlights (see Conference Reports) contain data and comments about these studies. Hydroxyurea used alone has not been effective against HIV; up until now findings from studies have shown that the combination of hydroxyurea+ddI can lower viral load in blood and in lymph tissue. The combination of AZT+hydroxyurea is not effectual. The accumulation of data so far has come from small pilot studies sponsored mostly by Bristol-Myers Squibb, although the ACTG started a trial in the Summer of `96.
منابع مشابه
Combination Therapy With Stavudine (d4T) Plus Didanosine (ddI) in Children With Human Immunodeficiency Virus Infection
Objectives. To evaluate the safety, tolerance, and antiviral activity of combination therapy with stavudine (d4T) plus didanosine (ddI) in symptomatic human immunodeficiency virus (HIV)-infected children. Methods. The study enrolled HIV-infected children who successfully completed Pediatric AIDS Clinical Trials Group (PACTG) protocol 240 (d4T versus zidovudine [ZDV] monotherapy) without disease...
متن کاملCombination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
OBJECTIVES To evaluate the safety, tolerance, and antiviral activity of combination therapy with stavudine (d4T) plus didanosine (ddI) in symptomatic human immunodeficiency virus (HIV)-infected children. METHODS The study enrolled HIV-infected children who successfully completed Pediatric AIDS Clinical Trials Group (PACTG) protocol 240 (d4T versus zidovudine [ZDV] monotherapy) without disease...
متن کاملIn vivo antagonism with zidovudine plus stavudine combination therapy.
Human immunodeficiency virus (HIV)-infected subjects receiving zidovudine were randomized either to add stavudine (d4T) or didanosine (ddI) to their current regimen or to switch to ddI or d4T monotherapy. After 16 weeks of therapy, the mean reduction in HIV RNA from baseline was 0.14 log(10) copies/mL in patients receiving d4T or zidovudine plus d4T. In subjects receiving ddI or ddI plus zidovu...
متن کاملLamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
Objective: To study the antiviral activity of lamivudine (3TC) plus zidovudine (ZDV), didanosine (ddI), or stavudine (d4T). Design: Randomized, placebo-controlled, partially double-blinded multicenter study. Setting: Adult AIDS Clinical Trials Units. Patients: Treatment-naive HIV-infected adults with 200–600 × 10 CD4 T lymphocytes/l. Interventions: Patients were openly randomized to a d4T or a ...
متن کاملToxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.
BACKGROUND Human immunodeficiency virus (HIV) therapy includes a backbone of nucleoside reverse-transcriptase inhibitors (NRTIs). Toxicities associated with NRTIs are not fully defined in children. METHODS We studied 2233 children < or =13 years of age who were perinatally infected with HIV and were receiving > or =2 NRTIs, to determine the relative toxicities of the 5 most common NRTI pairs:...
متن کامل